...
首页> 外文期刊>Pharmacological reports: PR >Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors.
【24h】

Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors.

机译:重复的丙咪嗪治疗可增强7-OH-DPAT诱导的大鼠活动亢进:多巴胺D2和D3受体的作用。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Previous studies have shown that antidepressant drugs with different pharmacological profiles, administered repeatedly, increase the locomotor hyperactivity induced by various dopaminomimetics, among others by (±)7- -hydroxydipropylaminotetralin (7-OH-DPAT). Since, according to a recent study, this drug shows a high affinity for not only dopamine D but also dopamine D receptors, a question arises whether dopamine D receptors are involved in the increase in 7-OH-DPAT-elicited locomotor hyperactivity induced by repeated treatment with antidepressant drugs. The aim of the present study was to investigate the effect of imipramine (IMI), administered repeatedly, on the hyperactivity induced by 7-OH-DPAT, a dopamine D receptor- preferring agonist. Male Wistar rats were treated with IMI (10 mg/kg po) either acutely (single dose) or repeatedly (twice daily for 14 days). The locomotor hyperactivity induced by 7-OH-DPAT (3 mg/kg sc) was measured in photoresistor actometers. The influence of nafadotride (0.2 and 0.4 mg/kg ip), a dopamine D -preferring antagonist or sulpiride (10 and 25 mg/kg ip), a dopamine D /D antagonist, on the 7-OH-DPAT-induced locomotor hyperactivity was studied. Nafadotride (in both doses used) or sulpiride (in the higher dose only) reduced (by about 50%) the hyperactivity induced by 7-OH-DPAT. Combined treatment with nafadotride (0.2 mg/kg) and sulpiride (25 mg/kg) completely abolished the effect of 7-OH-DPAT. IMI administered repeatedly (but not acutely) enhanced the 7-OH-DPAT-induced hyperactivity. Neither nafadotride, 0.2 mg/kg (or sulpiride, 10 mg/kg), given alone nor combined treatment with both these substances changed the hyperactivity induced by repeated treatment with IMI and 7-OH-DPAT (given 2 h after the last dose of IMI). Joint treatment with nafadotride, 0.2 mg/kg, and sulpiride, 25 mg/kg, completely abolished the enhancing effect of repeated treatment with IMI and 7-OH-DPAT. The above results indicate that both types of dopamine receptors, D and D , may play a substantial role in the mechanism of the 7-OH-DPAT-induced hyperactivity, as well as in the increase evoked by repeated treatment with IMI in rats.
机译:先前的研究表明,重复给药的具有不同药理学特征的抗抑郁药会增加由多种多巴胺模拟物(其中包括(±)7-羟基二丙基氨基四氢萘(7-OH-DPAT)等)引起的运动亢进。由于根据最近的研究,该药物不仅显示出对多巴胺D受体的高度亲和力,而且还显示出对多巴胺D受体的高度亲和力,因此产生了一个问题,即多巴胺D受体是否参与了由7-OH-DPAT引起的重复运动引起的运动亢进的增加用抗抑郁药治疗。本研究的目的是研究重复给药的丙咪嗪(IMI)对7-OH-DPAT(一种多巴胺D受体偏爱的激动剂)诱导的过度活跃的影响。雄性Wistar大鼠急性(单剂量)或反复(每天两次,每天两次,共14天)接受IMI(10 mg / kg口服)治疗。在光阻计中测量了由7-OH-DPAT(3 mg / kg sc)引起的运动过度活跃。 Nafadotride(0.2和0.4 mg / kg ip),多巴胺D拮抗剂或舒必利(10和25 mg / kg ip),多巴胺D / D拮抗剂对7-OH-DPAT诱导的运动亢进的影响被研究了。 Nafadotride(使用两种剂量)或sulpiride(仅使用较高剂量)可减少(约50%)由7-OH-DPAT诱导的过度活跃。联合使用萘法地特(0.2 mg / kg)和舒必利(25 mg / kg)的治疗完全消除了7-OH-DPAT的作用。反复(但不是急性)给予IMI可增强7-OH-DPAT诱导的机能亢进。单独或联合使用这两种物质的0.2 mg / kg萘法地利(或supipiride 10 mg / kg)均不能改变通过IMI和7-OH-DPAT的重复治疗(最后一次给药后2小时给予)引起的机能亢进。 IMI)。用0.2 mg / kg的萘法多利和25 mg / kg的舒必利联合治疗,完全消除了IMI和7-OH-DPAT重复治疗的增强作用。以上结果表明,两种类型的多巴胺受体D和D均可能在7-OH-DPAT诱导的机能亢进的机制中以及在反复用IMI引起的大鼠增加中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号